HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts.

Abstract
Until recently, progress in the treatment of patients with Ph(+) acute lymphoblastic leukaemia (ALL) has been limited, and long-term survival, even with high-dose intensified chemotherapy, is rare. Allogeneic stem cell transplantation is potentially curative, but treatment-related mortality and rate of disease recurrence are substantial. With the advent of the ABL-selective tyrosine kinase inhibitor STI571 (imatinib mesylate, Glivec), it has become apparent that the understanding of crucial leukaemogenic pathways at the molecular level can lead to the development of specific and selective agents. In recent clinical trials, imatinib has demonstrated significant anti-leukaemic efficacy in patients with advanced Ph(+) ALL, in conjunction with a remarkably favourable safety profile. Clinical resistance to imatinib develops rapidly, highlighting the limitations of using imatinib as a single agent; however, the value of imatinib as an element of treatment has become apparent. Resistance mechanisms have already been identified that will enable the development of rational strategies to prevent or overcome resistance. On the basis of available clinical results, combinations of imatinib with established anti-leukaemic agents, as well as with novel, molecularly targeted treatment modalities, will need to be evaluated in advanced Ph(+) ALL. Incorporation of imatinib in the first-line treatment of de novo Ph(+) ALL and in the setting of minimal residual disease is a promising therapeutic approach which is currently being studied in clinical trials. Better understanding of targeted therapies, including strategies based on recruitment of host immune functions, as well as the prudent use of active chemotherapy agents, may eventually improve the outlook for patients with Ph(+) ALL.
AuthorsOliver G Ottmann, Barbara Wassmann
JournalBest practice & research. Clinical haematology (Best Pract Res Clin Haematol) Vol. 15 Issue 4 Pg. 757-69 (Dec 2002) ISSN: 1521-6926 [Print] Netherlands
PMID12617875 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antineoplastic Agents
  • Benzamides
  • Enzyme Inhibitors
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
Topics
  • Antineoplastic Agents (therapeutic use)
  • Antineoplastic Protocols
  • Benzamides
  • Clinical Trials as Topic
  • Drug Interactions
  • Drug Resistance, Neoplasm
  • Enzyme Inhibitors (therapeutic use)
  • Humans
  • Imatinib Mesylate
  • Neoplasm, Residual (diagnosis, therapy)
  • Piperazines (metabolism, pharmacology, therapeutic use)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)
  • Protein-Tyrosine Kinases (antagonists & inhibitors)
  • Pyrimidines (metabolism, pharmacology, therapeutic use)
  • Recurrence
  • Salvage Therapy (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: